Cornaglia-Ferraris P, Mariottini G L, Ponzoni M
Pediatric Oncology Research Laboratory, G. Gaslini Children's Hospital, Genoa, Italy.
Cancer Lett. 1992 Jan 31;61(3):215-20. doi: 10.1016/0304-3835(92)90290-c.
We have investigated the effects of retinoic acid (RA), human recombinant gamma interferon (gamma-IFN), and the association of both agents on the growth of human neuroblastoma (NB) cells in [CD1(nu/nu)] nude mice. Two human NB cell lines, namely LAN-5 and GI-LI-N, were previously adapted to grow in syngeneic animals for 7 consecutive passages. At the eighth passage, only animals which developed 10-mm diameter tumors within 40 days from xenograft were admitted to the study. RA and/or gamma-IFN were administered subcutaneously 3-5 days per week for 3 consecutive weeks. The number of days necessary for each tumor mass to grow up to 20 mm diameter (in vivo doubling time, ivDT) was then evaluated. Tumor growth was significantly inhibited in gamma-IFN (P less than 0.005) and RA (P less than 0.05) treated mice grafted with GI-LI-N. The combination of the two agents did not further enhance ivDT. The tumor growth inhibition was not statistically significant in LAN-5 bearing mice treated with RA or gamma-IFN alone, while a synergistic effect between the two drugs was observed (P less than 0.05). We conclude that parenteral combined administration of RA and gamma-IFN may prove to be useful in inhibiting the growth of tumors derived from human NB cells resistant to single inducers.
我们研究了视黄酸(RA)、人重组γ干扰素(γ-IFN)以及这两种药物联合使用对[CD1(nu/nu)]裸鼠体内人神经母细胞瘤(NB)细胞生长的影响。两种人NB细胞系,即LAN-5和GI-LI-N,之前已连续7代适应在同基因动物体内生长。在第8代时,仅纳入那些在异种移植后40天内长出直径达10毫米肿瘤的动物进行研究。每周皮下注射RA和/或γ-IFN 3 - 5天,连续注射3周。然后评估每个肿瘤块生长至直径20毫米所需的天数(体内倍增时间,ivDT)。在接种GI-LI-N的小鼠中,γ-IFN(P < 0.005)和RA(P < 0.05)治疗组的肿瘤生长受到显著抑制。两种药物联合使用并未进一步延长ivDT。单独用RA或γ-IFN治疗接种LAN-5的小鼠时,肿瘤生长抑制无统计学意义,而两种药物之间观察到协同作用(P < 0.05)。我们得出结论,胃肠外联合给予RA和γ-IFN可能被证明对抑制源自对单一诱导剂耐药的人NB细胞的肿瘤生长有用。